Akeso’s ivonescimab has emerged as a key player in the rapidly advancing biotech landscape in China, following promising results from the Harmoni-6 trial. This first-in-class PD-1xVEGF bispecific antibody demonstrated a statistically significant 34% improvement in overall survival for patients with untreated, advanced squamous non-small cell lung cancer (NSCLC) when combined with chemotherapy. This groundbreaking outcome positions ivonescimab as the first regimen to outperform the established standard of a PD-1 inhibitor plus chemotherapy in this patient population.
The interim analysis of the ongoing Phase 3 Harmoni-6 trial was noteworthy not only for its findings but also for being the first China-specific dataset presented at a plenary session at the American Society of Clinical Oncology (ASCO) annual meeting. Observers had previously viewed a 30% overall survival improvement as a significant achievement, making the 34% improvement reported even more striking. The significance was further underscored by a p-value of 0.0017, comfortably within the pre-defined statistical significance threshold of 0.0049.
Experts in the oncology community reacted positively to the findings. Dr. David Spigel, a leading voice in lung cancer research, described the results as “certainly very encouraging,” highlighting the potential for better treatment pathways for patients facing challenging cancer diagnoses.
Initially, ivonescimab gained attention in 2024 by outperforming Merck & Co.’s Keytruda on progression-free survival in a head-to-head study. However, doubts remained about whether this bispecific could achieve similar overall survival benefits when evaluating its effectiveness in a more significant clinical context. The Harmoni-6 trial results alleviated some of this skepticism, revealing a median overall survival time of 27.9 months compared to the control arm’s 23.7 months—an extension attributed to ivonescimab and chemotherapy.
The survival benefits were consistent across various patient demographics, with improvements seen in both PD-L1-negative and PD-L1-positive groups. The study also delineated the control arm’s performance against historical benchmarks, reinforcing the credibility of the ivonescimab regimen.
However, while there is optimism surrounding ivonescimab, some researchers, including Dr. Julie Brahmer from Johns Hopkins, offered a more critical perspective. Brahmer emphasized the need for a longer follow-up period as previous experiences with VEGF inhibitors suggested that early signals of improvement could diminish over time. Her concerns were echoed by market analysts who questioned the maturity of the Harmoni-6 data, suggesting more extended observation is needed to draw definitive conclusions.
Brahmer also scrutinized the study’s eligibility criteria, noting that the exclusion of certain patients, such as those showing significant tumor invasion near major vessels or with a history of severe bleeding, raised questions about the generalizability of the results. Furthermore, concerns regarding patient demographics were highlighted, as the trial disproportionately involved male participants and excluded older patients—groups typically engaged in global studies.
As the oncology community continues to dissect and evaluate harmoni-6 findings, questions linger about ivonescimab’s place in the broader treatment landscape, particularly regarding its safety profile and applicability to diverse global populations. The ultimate implications of these findings will depend on subsequent trial results and further analysis, as stakeholders await further navigations in this promising but complex field of cancer therapy.
